论文信息 - First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. - 字舞流文

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han | G. Jiang | H. Pan | S. How | C. Liam | Y. Wu | C. Zhou | G. Wu | X. Liu | Z. Zhong | Y. Cheng | L. Chen | S. Qin | Y. Zhu | H. Liang | E. Li | M. C. Fernando | Y. Zhang | F. Xia | Y. Zuo | S. Lu | C. Huang